<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A large proportion of lower-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) respond to erythropoiesis-stimulating agents (ESA), but most responses are transient </plain></SENT>
<SENT sid="1" pm="."><plain>We updated a previously reported cohort of lower-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients treated with ESA and analyzed outcomes after ESA failure </plain></SENT>
<SENT sid="2" pm="."><plain>In 120 patients with primary resistance and 66 patients with relapse after an initial response to ESA, the 5-year cumulative incidence of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) after failure was 18.9% and 11.6%, respectively (P=0.20) </plain></SENT>
<SENT sid="3" pm="."><plain>Median overall survival (OS) after failure was 40.1 and 44.9 months (P=0.35), respectively </plain></SENT>
<SENT sid="4" pm="."><plain>We further categorized patients as 'early failures' (including resistance and relapse after &lt;6 months of response), or 'later failures' (that is, relapse after î‹¶6 months) </plain></SENT>
<SENT sid="5" pm="."><plain>The 5-year cumulative incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and median OS after failure in early and later failure were 21.6% and 9% (P=0.02) and 36.7 and 54.3 months (P=0.02), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Early failure to ESA and a baseline diagnosis of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>)-1 were independent prognostic factors for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> progression and, along with <z:mp ids='MP_0004027'>trisomy</z:mp> 8, for shorter OS </plain></SENT>
<SENT sid="7" pm="."><plain>Median OS from treatment <z:hpo ids='HP_0003674'>onset</z:hpo> was 40, 90.7 and 65.8 months in early failure, later failure and no relapse, respectively (P=0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Lower-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with early failure to ESA have a relatively unfavorable outcome, and should be offered alternative treatments </plain></SENT>
</text></document>